What were End­points read­ers tun­ing in­to this year? Here’s a look at our 15 most pop­u­lar re­ports of the year (so far)

At the be­gin­ning of this year, I laid out a ba­sic ob­jec­tive for End­points News as we head­ed to our 5th an­niver­sary. We’ve long been do­ing a fine job cov­er­ing the break­ing news in R&D — if I do say so my­self — but we need­ed to ex­pand our hori­zons on in­dus­try cov­er­age, in­crease the staff and go much, much deep­er when the sto­ries de­mand­ed it.

In a phrase: broad­er and deep­er.

It’s safe to say, based on our dai­ly web traf­fic, that you all seemed to like this idea. We’ve dou­bled the staff — thanks to a grow­ing group of paid sub­scribers — ramped up the dai­ly re­port and now pub­lish a reg­u­lar slate of in-depth ar­ti­cles. And traf­fic — those clicks you al­ways read about — have gone up in vol­ume too. Month­ly ses­sions are up 43%, to close to 1.5 mil­lion. Unique read­ers are up 63%, to 874,480 in Oc­to­ber, af­ter set­ting a record of close to a mil­lion the month be­fore. Page views are run­ning at 3 mil­lion-plus a month. And the over­all num­ber of sub­scribers has surged to 124,000.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE